General Information of Drug (ID: DMBJN19)

Drug Name
Rontalizumab Drug Info
Indication
Disease Entry ICD 11 Status REF
Systemic lupus erythematosus 4A40.0 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMBJN19

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Interferon alpha (IFNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Interferon alfa-n3 DMTZNQ9 Human immunodeficiency virus infection 1C62 Approved [2]
Alfaferone DMCKPUR Hairy cell leukaemia 2A82.2 Approved [3]
P1101 DM5DRMY Polycythemia vera 2A20.4 Phase 3 [4]
Human interferon alpha oral DMKQ3MC Hepatitis C virus infection 1E51.1 Phase 2 [5]
IFN-alpha DM4H8EZ Hepatitis C virus infection 1E51.1 Phase 2 [6]
Interferon-alpha lozenge DM8YF01 Behcet disease 4A62 Phase 2 [7]
IFN alpha kinoid DMLEVFW Human immunodeficiency virus infection 1C62 Phase 1/2 [8]
NG-641 DMITVHM Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
AGS-009 DMU21JF Systemic lupus erythematosus 4A40.0 Phase 1 [10]
Ad-IFN-alpha DMM45P9 Bladder cancer 2C94 Phase 1 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interferon alpha (IFNA) TT95SOA NOUNIPROTAC Not Available [1]

References

1 Clinical pipeline report, company report or official report of Genentech (2011).
2 Clinical pipeline report, company report or official report of Hemispherx Biopharma.
3 Natural leukocyte interferon alpha (Alfaferone) combined with ribavirin in the treatment of patients with HCV-related cirrhosis: our experience. Infection. 2011 Oct;39(5):433-7.
4 Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. Am J Hematol. 2015 Apr;90(4):288-94.
5 Low-dose oral natural human interferon-alpha in 29 patients with HIV-1 infection: a double-blind, randomized, placebo-controlled trial. AIDS. 1992 Jun;6(6):563-9.
6 WO patent application no. 2009,0153,36, Controlled release interferon drug products and treatment of hcv infection using same.
7 Interferon-alpha. Amarillo Biosciences. Curr Opin Investig Drugs. 2002 May;3(5):693-7.
8 Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid. Arthritis Rheum. 2013 Feb;65(2):447-56.
9 Clinical pipeline report, company report or official report of PsiOxus Therapeutics.
10 Emerging Therapies for Systemic Lupus Erythematosus - Focus on Targeting Interferon-alpha. Clin Immunol. 2012 June; 143(3): 210-221.
11 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.